M. Rabadán

发表

Is hormone therapy a protective factor for late hematuria after high-dose radiotherapy in prostate cancer?

F. García-Vicente, A. Zapatero, C. Ferrer, 2008, Urology.

Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials.

L. Martínez-Piñeiro, E. Solsona, A. Gimeno, 2008, European urology.

Long-term results of two prospective bladder-sparing trimodality approaches for invasive bladder cancer: neoadjuvant chemotherapy and concurrent radio-chemotherapy.

A. Zapatero, C. Martín de Vidales, M. Rabadán, 2012, Urology.

Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial.

L. Martínez-Piñeiro, E. Solsona, S. Isorna, 2005, The Journal of urology.

Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial.

L. Martínez-Piñeiro, J. Portillo, E. Solsona, 2015, European urology.

Invasive bladder cancer: A single‐institution experience with bladder‐sparing approach

L. Cerezo, A. Zapatero, C. Martín de Vidales, 2000, International journal of cancer.

Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model.

L. Martínez-Piñeiro, J. Portillo, E. Solsona, 2009, The Journal of urology.

The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables.

L. Martínez-Piñeiro, J. Portillo, E. Solsona, 2011, European urology.

The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables.

L. Martínez-Piñeiro, J. Portillo, E. Solsona, 2011, European urology.

Long-term results after high-dose radiotherapy and adjuvant hormones in prostate cancer: how curable is high-risk disease?

F. García-Vicente, A. Zapatero, C. Martín de Vidales, 2011, International journal of radiation oncology, biology, physics.

188 TREATMENT OF CARCINOMA IN SITU OF THE BLADDER ASSOCIATED OR NOT ASSOCIATED TO NON-MUSCLE INVASIVE TRANSITIONAL CARCINOMA USING TWO DIFFERENT BCG DOSES: THE STANDARD OR ONE-THIRD DOSE. A FIVE YEAR FOLLOW-UP

M. Unda-Urzáiz, J. Fernández-Gómez, R. Madero-Jarabo, 2010 .